Dhruvitkumar S. Sutaria

1.4k total citations · 1 hit paper
34 papers, 1.1k citations indexed

About

Dhruvitkumar S. Sutaria is a scholar working on Molecular Biology, Molecular Medicine and Cancer Research. According to data from OpenAlex, Dhruvitkumar S. Sutaria has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 11 papers in Molecular Medicine and 9 papers in Cancer Research. Recurrent topics in Dhruvitkumar S. Sutaria's work include MicroRNA in disease regulation (9 papers), Antibiotic Resistance in Bacteria (8 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Dhruvitkumar S. Sutaria is often cited by papers focused on MicroRNA in disease regulation (9 papers), Antibiotic Resistance in Bacteria (8 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Dhruvitkumar S. Sutaria collaborates with scholars based in United States, South Korea and Australia. Dhruvitkumar S. Sutaria's co-authors include Thomas D. Schmittgen, Mohamed Badawi, Mitch A. Phelps, Jinmai Jiang, Ola A. Elgamal, Xiaohua Zhu, Steven Pomeroy, Jeffrey J. Chalmers, Krista La Perle and Zhiliang Xie and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Dhruvitkumar S. Sutaria

30 papers receiving 1.1k citations

Hit Papers

Comprehensive toxicity and immunogenicity studies reveal ... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells
    2017 447 citations Xiaohua Zhu, Mohamed Badawi et al. Journal of Extracellular Vesicles profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dhruvitkumar S. Sutaria United States 14 777 426 125 97 94 34 1.1k
Liang Zhu China 20 851 1.1× 474 1.1× 39 0.3× 150 1.5× 198 2.1× 70 1.4k
Rongying Ou China 20 711 0.9× 477 1.1× 39 0.3× 56 0.6× 126 1.3× 53 1.1k
Yanbin Zhou China 22 646 0.8× 248 0.6× 98 0.8× 98 1.0× 389 4.1× 50 1.3k
Shouying Du China 12 946 1.2× 468 1.1× 27 0.2× 128 1.3× 34 0.4× 38 1.4k
Xinying Xue China 17 356 0.5× 266 0.6× 43 0.3× 73 0.8× 286 3.0× 54 1.0k
Meena Prasad United States 5 520 0.7× 256 0.6× 28 0.2× 59 0.6× 53 0.6× 14 908
Mary Ferguson United States 14 557 0.7× 295 0.7× 24 0.2× 51 0.5× 175 1.9× 20 1.0k
Bingbing Qiao China 11 323 0.4× 180 0.4× 38 0.3× 69 0.7× 55 0.6× 14 533

Countries citing papers authored by Dhruvitkumar S. Sutaria

Since Specialization
Citations

This map shows the geographic impact of Dhruvitkumar S. Sutaria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dhruvitkumar S. Sutaria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dhruvitkumar S. Sutaria more than expected).

Fields of papers citing papers by Dhruvitkumar S. Sutaria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dhruvitkumar S. Sutaria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dhruvitkumar S. Sutaria. The network helps show where Dhruvitkumar S. Sutaria may publish in the future.

Co-authorship network of co-authors of Dhruvitkumar S. Sutaria

This figure shows the co-authorship network connecting the top 25 collaborators of Dhruvitkumar S. Sutaria. A scholar is included among the top collaborators of Dhruvitkumar S. Sutaria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dhruvitkumar S. Sutaria. Dhruvitkumar S. Sutaria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sutaria, Dhruvitkumar S., Rodney A. Prell, Wendy Halpern, et al.. (2025). Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients. Clinical and Translational Science. 18(7). e70298–e70298. 1 indexed citations
2.
Doz, François, Michela Casanova, Karsten Nysom, et al.. (2025). Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.. Journal of Clinical Oncology. 43(16_suppl). 10004–10004.
3.
Mandlekar, Sandhya, Dhruvitkumar S. Sutaria, Yixuan Zou, et al.. (2024). Evaluation of Patient‐Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules. Clinical Pharmacology & Therapeutics. 116(3). 782–794. 4 indexed citations
4.
Mody, Hardik, Dhruvitkumar S. Sutaria, & Dale Miles. (2024). Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies. Clinical Pharmacology & Therapeutics. 115(6). 1233–1250. 3 indexed citations
5.
Jiao, Yuanyuan, Jun Yan, Dhruvitkumar S. Sutaria, et al.. (2024). Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models. Antimicrobial Agents and Chemotherapy. 68(3). e0139423–e0139423.
6.
Jiao, Yuanyuan, Jun Yan, Michael Vicchiarelli, et al.. (2023). Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice. Antimicrobial Agents and Chemotherapy. 67(5). e0019723–e0019723. 5 indexed citations
7.
Sutaria, Dhruvitkumar S., Priya Agarwal, Dale Miles, et al.. (2022). Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications. Clinical and Translational Science. 15(12). 2989–2999. 3 indexed citations
8.
Sutaria, Dhruvitkumar S., Adam Harris, Ryan Johnson, et al.. (2022). Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer. Pharmaceutics. 14(10). 2101–2101. 7 indexed citations
9.
Kotani, Naoki, Justin Wilkins, Janet R. Wade, et al.. (2022). Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. Cancer Chemotherapy and Pharmacology. 90(6). 511–521. 4 indexed citations
10.
11.
Jiao, Yuanyuan, Bartolomé Moyá, Alexandre Prehn Zavascki, et al.. (2019). Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy. 63(7). 21 indexed citations
12.
Bulitta, Jürgen B., Yuanyuan Jiao, Cornelia B. Landersdorfer, et al.. (2019). Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. Pharmaceutics. 11(7). 323–323. 5 indexed citations
13.
Jiao, Yuanyuan, Tae‐Hwan Kim, Xun Tao, et al.. (2018). First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. European Journal of Pharmaceutical Sciences. 123. 416–428. 8 indexed citations
14.
Sutaria, Dhruvitkumar S., Bartolomé Moyá, Kari B. Green, et al.. (2018). First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 62(6). 60 indexed citations
15.
Sutaria, Dhruvitkumar S., Jinmai Jiang, Ana Clara P. Azevedo‐Pouly, et al.. (2017). Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma. Non-Coding RNA. 3(3). 24–24. 18 indexed citations
16.
Zhu, Xiaohua, Mohamed Badawi, Steven Pomeroy, et al.. (2017). Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. Journal of Extracellular Vesicles. 6(1). 1324730–1324730. 447 indexed citations breakdown →
17.
Sutaria, Dhruvitkumar S., Mohamed Badawi, Mitch A. Phelps, & Thomas D. Schmittgen. (2017). Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading. Pharmaceutical Research. 34(5). 1053–1066. 113 indexed citations
18.
Jiang, Jinmai, Ana Clara P. Azevedo‐Pouly, Roxana S. Redis, et al.. (2016). Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Oncotarget. 7(33). 53165–53177. 39 indexed citations
19.
Sutaria, Dhruvitkumar S., et al.. (2012). Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. International Journal of Oncology. 41(6). 2260–2268. 56 indexed citations
20.
Chaudhary, Abhishek, Dhruvitkumar S. Sutaria, Ying Huang, Jeffrey Wang, & Sunil Prabhu. (2011). Chemoprevention of Colon Cancer in a Rat Carcinogenesis Model Using a Novel Nanotechnology-Based Combined Treatment System. Cancer Prevention Research. 4(10). 1655–1664. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liang Zhu Breakdown of academic impact, for papers by Rongying Ou Breakdown of academic impact, for papers by Yanbin Zhou Breakdown of academic impact, for papers by Shouying Du Breakdown of academic impact, for papers by Xinying Xue Breakdown of academic impact, for papers by Meena Prasad Breakdown of academic impact, for papers by Mary Ferguson Breakdown of academic impact, for papers by Bingbing Qiao
Rankless by CCL
2026